Back to search
Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive trials you may qualify forThis is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G…
This study is the first randomized, open-label, national, multicenter, phase II study assessing the efficacy and safety of OCLU in subjects with pretreated prog…
To evaluate safety and efficacy of everolimus (Afinitor®) in Chinese adult patients with local advanced or metastatic, well differentiated progressive pancreati…
This study is a multi-center, prospective, non-interventional (NI) study evaluating the safety and efficacy of sunitinib in Chinese patients with progressive, u…
A descriptive, prospective (partly retrospective), multisite, observational study conducted in France in adult patients treated for a well differentiated, unres…
The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.
This phase II trial studies how well dovitinib lactate works in treating patients with pancreatic neuroendocrine tumors. Dovitinib lactate may stop the growth o…
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive…
The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for br…
This study randomized patients with advanced pancreatic islet cell tumors to receive either sunitinib or placebo. Patients who were randomized to sunitinib rece…